Ternary Therapeutics
PrivateLast Round
Seed
Mar 16, 2026
Total Funding Raised
$4.6M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ternary Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Seed round in March 2026.
Ternary Therapeutics is a biotechnology company that develops an AI-driven platform for the rational design of molecular glue therapeutics targeting immunological disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ternary Therapeutics Comparables
Compare Ternary Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TenAces Biosciences | 87% | |
| Axiom Therapeutics | 82% | |
| Celeris Therapeutics | 80% |
For institutional investors. Book with your work email.
Ternary Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 16, 2026 | ||||
| Seed | Feb 27, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ternary Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pace Ventures | Seed |
| Daphni | Seed |
| UK Innovation & Science Seed Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 19, 2026
Grew 21% QoQ, from 14 to 17 employees.
- Jun 1, 2026
Grew 25% QoQ from 12 to 15 employees.
For institutional investors. Book with your work email.
Ternary Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ternary Therapeutics's valuation, stock price, and market status.
Is Ternary Therapeutics a public or private company?
Ternary Therapeutics is a private company.
What is the current stock price of Ternary Therapeutics?
Ternary Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ternary Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ternary Therapeutics worth (valuation)?
Valuation information for Ternary Therapeutics is not publicly available.
Can I buy Ternary Therapeutics stock?
Ternary Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ternary Therapeutics's last funding round?
Ternary Therapeutics's most recent funding round was Seed on March 16, 2026.
Who are the main investors in Ternary Therapeutics?
Key investors in Ternary Therapeutics include Daphni.
Will Ternary Therapeutics IPO soon?
No public IPO plans have been announced for Ternary Therapeutics.
How can I track Ternary Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ternary Therapeutics's shares on secondary markets.